The enigma of in vivo oxidative stress assessment: Isoprostanes as an emerging target

Scandinavian Journal of Food and Nutrition

Volumn 51, Issue 2, 2007, Pages 48-61

  Basu, Samar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antioxidants; Free radicals; Human; Inflammation; Isoprostanes; Oxidative strain; Oxidative stress

Indexed keywords

ANTIOXIDANT; ARACHIDONIC ACID; ISOPROSTANE DERIVATIVE;

ACUTE DISEASE; ANALYTIC METHOD; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; BODY FLUID; CELL AGING; CELL DAMAGE; CHRONIC DISEASE; HUMAN; OXIDATIVE STRESS; REVIEW; TISSUE INJURY;

EID: 34250621313     PISSN: 17482976     EISSN: 17482984     Source Type: Journal    
DOI: 10.1080/17482970701411642     Document Type: Review

References (129)

1. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
2. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-13.
3. 2-isoprostane induced prostaglandin formation in the rabbit. Free Radic Res 2006; 40: 273-7.
4. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004; 38: 105-22.
5. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-6.
6. Serhan CN. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 2005; 8: 115-21.
7. 2α from physiology to new principles in inflammation. Medicinal Research Reviews 2006; On-line published December 2006.
8. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993;57:715-24S; discussion 724-5S.
9. Basu S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicology 2003; 189: 113-27.
10. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
11. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 1998; 10: 248-53.
12. Nishikawa T, Edelstein D, Du XL, Matsumaura T, Kaneda Y, Yorek MA. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
13. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11: 66-75.
14. Nemoto S, Finkel T. Ageing and the mystery at Arles. Nature 2004; 429: 149-52.
15. Nugteren DH, Vonkeman H, van Dorf DA. Nonenzymatic conversion of all cis 8,11,14-eicosapentanoic acid into PGE1. Recl Trav Chim Pays-bas 1967; 86: 1237-45.
16. Porter NA, Funk MO. Letter: Peroxy radical cyclization as a model for prostaglandin biosynthesis. J Org Chem 1975; 40: 3614-5.
17. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 2000; 32: 377-85.
18. 2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992; 89: 10721-5.
19. 2-isoprostanes after hydrolysis of lipids in tissues. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 149-52.
20. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid Redox Signal 2005; 7: 221-35.
21. Sodergren E, Cederberg J, Vessby B, Basu S. Vitamin E reduces lipid peroxidation in experimental hepatotoxicity in rats. Eur J Nutr 2001; 40: 10-6.
22. 2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992; 90: 2502-7.
23. Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak S. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener 2007; 2: 2.
24. 2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem Pharmacol 1994; 47: 1173-7.
25. Basu S. Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Biochem Biophys Res Commun 1999; 254: 764-7.
26. 2α, 8-isoprostane, in H2O2-induced derangements of pulmonary artery endothelial cell barrier function. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 9-16.
27. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999; 459: 259-62.
28. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res 2000; 47: 410-8.
29. 2α: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 319-25.
30. 2α excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
31. 2α-VI in human urine by gas chromatography/mass spectrometry. Anal Biochem 1998; 262: 45-56.
32. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005; 38: 698-710.
33. 4 poisoning. Free Radic Biol Med 2005; 38: 711-8.
34. Wiklund L, Sharma HS, Basu S. Circulatory arrest as a model for studies of global ischemic injury and neuroprotection. Ann N Y Acad Sci 2005; 1053: 205-19.
35. Basu S, Liu X, Nozari A, Rubertsson S, Miclescu A, Wiklund L. Evidence for time-dependent maximum increase of free radical damage and eicosanoid formation in the brain as related to duration of cardiac arrest and cardio-pulmonary resuscitation. Free Radic Res 2003; 37: 251-6.
36. Basu S, Nozari A, Liu XL, Rubertsson S, Wiklund L. Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest. FEBS Lett 2000; 470: 1-6.
37. Liu XL, Nozari A, Basu S, Ronquist G, Rubertsson S, Wiklund L. Neurological outcome after experimental cardiopulmonary resuscitation: a result of delayed and potentially treatable neuronal injury? Acta Anaesthesiol Scand 2002; 46: 537-46.
38. Liu XL, Wiklund L, Nozari A, Rubertsson S, Basu S. Differences in cerebral reperfusion and oxidative injury after cardiac arrest in pigs. Acta Anaesthesiol Scand 2003; 47: 958-67.
39. Idris AH, Roberts LJ II, Caruso L, Showstark M, Layon AJ, Becker LB, et al. Oxidant injury occurs rapidly after cardiac arrest, cardiopulmonary resuscitation, and reperfusion. Crit Care Med 2005; 33: 2043-8.
40. Basu S, Hellberg A, Ulus AT, Westman J, Karacagil S. Biomarkers of free radical injury during spinal cord ischemia. FEBS Lett 2001; 508: 36-8.
41. 2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95: 2492-9.
42. Miclescu A, Basu S, Wiklund L. Methylene blue added to hypertonic-hyperoncotic solution increases survival in experimental cardiac arrest. Crit Care Med 2006; 34: 2806-16.
43. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
44. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-203.
45. O'Byrne S, Forte P, Roberts LJ II, et al. Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes 2000; 49: 857-62.
46. Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med 2002; 251: 69-76.
47. Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 1624-8.
48. Gleisner A, Martinez L, Pino R, Rojas IG, Martinez A, Asenjo S. Oxidative stress markers in plasma and urine of prepubertal patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2006; 19: 995-1000.
49. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368: 225-9.
50. Gopaul NK, Manraj MD, Hebe A, Lee Kwai Yan S, Jonston A, Carrier MJ. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001; 44: 706-12.
51. 2α using liquid chromatography-tandem mass spectrometry: increased excretion in diabetics. Prostaglandins Other Lipid Mediat 2000; 62: 173-81.
52. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-34.
53. 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-5.
54. 2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-8.
55. 2-isoprostane concentrations in hypercholesterolemic humans only at doses of 800 IU or higher. Free Radic Biol Med 2002; 33: S412.
56. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999; 83: 1330-3.
57. Cracowski JL, Ploin D, Bessard J, Braguet JP, Stanke-Labesque F, Mallion JM. Formation of isoprostanes in children with type IIa hypercholesterolemia. J Cardiovasc Pharmacol 2001; 38: 228-31.
58. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-34.
59. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17: 3236-41.
60. 2α, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43: 492-9.
61. Ulus AT, Aksoyek A, Ozkan M, Katircioglu SF, Basu S. Cardiopulmonary bypass as a cause of free radical-induced oxidative stress and enhanced blood-borne isoprostanes in humans. Free Radic Biol Med 2003; 34: 911-7.
62. 2α in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 1997; 96: 3314-20.
63. Berg K, Wiseth R, Bjerve K, Brurok H, Gunnes S, Skara S. Oxidative stress and myocardial damage during elective percutaneous coronary interventions and coronary angiography. A comparison of blood-borne isoprostane and troponin release. Free Radic Res 2004; 38: 517-25.
64. 2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001; 37: 76-80.
65. Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006; 41: 1678-83.
66. 2-isoprostanes in patients with severe heart failure. Heart 2000; 84: 439-40.
67. 2α in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536-9.
68. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
69. 2-isoprostane formation in elderly men. Atherosclerosis 2005; 181: 201-7.
70. Ahmadzadehfar H, Oguogho A, Efthimiou Y, Kritz H, Sinzinger H. Passive cigarette smoking increases isoprostane formation. Life Sci 2006; 78: 894-7.
71. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-20.
72. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 2000; 35: 967-74.
73. Baraldi E, Ghiro L, Piovan V, Carraro S, Ciabattoni G, Barnes PJ. Increased exhaled 8-isoprostane in childhood asthma. Chest 2003; 124: 25-31.
74. Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-9.
75. 2α isoprostane in cystic fibrosis. Lipids 1999; 34: 551-6.
76. Ciabattoni G, Davi G, Collura M, Iapichino L, Pardo F, Ganchi A. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med 2000; 162: 1195-201.
77. Montuschi P, Kharitonov SA, Ciabattoni G, Corradi M, van Rensen L, Geddes DM. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000; 55: 205-9.
78. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 1038-42.
79. 2α-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158: 1709-14.
80. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitnov SA. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.
81. Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitnov SA. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158: 1524-7.
82. Morris JM, Gopaul NK, Endresen MJ, Knight M, Linton EA, Dhir S. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 1195-9.
83. Ishihara O, Hayashi M, Osawa H, Kobayashi K, Takeda S, Vessby B. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancy. Free Radic Res 2004; 38: 913-8.
84. Regan CL, Levine RJ, Baird DD, Ewell MG, Martz KL, Sibai BM. No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol 2001; 185: 572-8.
85. Walsh SW, Vaughan JE, Wang Y, Roberts LJ II. Placental isoprostane is significantly increased in preeclampsia. Faseb J 2000; 14: 1289-96.
86. Barden A, Ritchie J, Walters B, Croft KD, Walters BN, Michael CA. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 2001; 38: 803-8.
87. Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN, Michael CA. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clin Sci (Lond) 1996; 91: 711-8.
88. Perrone S, Longini M, Bellieni CV, et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem 2007; 40: 177-80.
89. 2-isoprostane concentration in probable AD. Neurology 1999; 52: 562-5.
90. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ II, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 1999; 155: 863-8.
91. 2α-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809-12.
92. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med 1999; 27: 463-9.
93. 4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002; 52: 175-9.
94. 2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann Neurol 2000; 48: 950.
95. 2-isoprostanes are elevated in Huntington's disease. Neurology 1999; 52: 1104-5.
96. 2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 2003; 85: 645-50.
97. 2-isoprostane excretion rates in migraine. Clin Sci (Lond) 2002; 102: 39-43.
98. Monga M, Dunn K, Rajasekaran M. Characterization of ultrastructural and metabolic abnormalities in semen from men with spinal cord injury. J Spinal Cord Med 2001; 24: 41-6.
99. 2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci Lett 2007; 414: 233-6.
100. Camphausen K, Ménard C, Sproull M, Goley E, Basu S, Coleman C. Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated. J Radiation Oncology, Biology, Physics 2003; 58: 1536-9.
101. 2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-6.
102. 2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002; 58: 190-7.
103. 2-isoprostanes formation in kidney transplantation. Clin Transplant 2001; 15: 58-62.
104. Basu S, Meisert I, Eggensperger E, Krieger E, Krenn CG. Time course attenuation of ischemia-reperfusion injury by propofol in human renal transplantation. Redox Report in press.
105. 2-isoprostanes in kidney transplant patients: relationship with inflammatory markers. Transplant Proc 2005; 37: 3842-3.
106. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommsoli R. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106: 2800-5.
107. 2α in different rheumatic diseases. Ann Rheum Dis 2001; 60: 627-31.
108. Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum 2001; 44: 1143-8.
109. Stein CM, Tanner SB, Awad JA, Roberts LJ II, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146-50.
110. Wolfram RM, Budinsky AC, Eder A, Presenhuber C, Nell A, Sperr W. Salivary isoprostanes indicate increased oxidation injury in periodontitis with additional tobacco abuse. Biofactors 2006; 28: 21-31.
111. Sinzinger H, Kaliman J, Oguogho A. Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers. Lymphology 2000; 33: 24-31.
112. 2 levels in patients with probable AD. Neurology 1999; 53: 1495-8.
113. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. Faseb J 1998;12:1777-83.
114. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med 1999; 27: 463-9.
115. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 2001; 288: 275-9.
116. Sinaiko AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu S. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 2005; 111: 1985-91.
117. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice Nat Med 1998; 4: 1189-92.
118. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001; 285: 1178-82.
119. Smedman A, Vessby B, Basu S. Isomer-specific effects of conjugated linoleic acid on lipid peroxidation in humans: regulation by alpha-tocopherol and cyclooxygenase-2 inhibitor. Clin Sci (Lond) 2004; 106: 67-73.
120. 2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000; 102: 539-45.
121. Weinberg RB, VanderWerken BS, Anderson RA, Stegner JE, Thomas MJ. Pro-oxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet. Arterioscler Thromb Vasc Biol 2001; 21: 1029-33.
122. Davi G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-8.
123. Meagher EA, Barry OP, Burke A, Luccy MR, Lawson JA, Rokach J. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999; 104: 805-13.
124. Basu S, Lee R, Dunster C, Kelly FJ. Lipid peroxidation biomarker changes in humans in response to increasing doses of α-tocopherol. Proc NY Acad Sci 2004;P12.
125. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
126. Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb 2002; 32: 359-60.
127. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-11.
128. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-7.
129. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-23.